Carisma Therapeutics Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Carisma Therapeutics Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q3 2024.
  • Carisma Therapeutics Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$12.7M, a 40.7% increase year-over-year.
  • Carisma Therapeutics Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$63.8M, a 22.8% increase year-over-year.
  • Carisma Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$86.9M, a 41.9% decline from 2022.
  • Carisma Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$61.2M, a 18122% decline from 2021.
  • Carisma Therapeutics Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$336K, a 98.5% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$63.8M -$12.7M +$8.7M +40.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$72.5M -$11.2M +$8.71M +43.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-11-07
Q1 2024 -$81.2M -$19M +$5.66M +23% Jan 1, 2024 Mar 31, 2024 10-Q 2024-11-07
Q4 2023 -$86.9M -$21M -$4.22M -25.2% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-01
Q3 2023 -$82.7M -$21.4M -$3.08M -16.8% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$79.6M -$19.9M -$5.03M -33.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-11-07
Q1 2023 -$74.6M -$24.6M -$13.3M -118% Jan 1, 2023 Mar 31, 2023 10-Q 2024-11-07
Q4 2022 -$61.2M -$16.7M -$25.7M -287% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 -$35.5M -$18.3M -$90M -126% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $54.5M -$14.8M +$10.6M +41.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $43.9M -$11.3M +$44.2M +79.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$336K $8.94M +$24M Oct 1, 2021 Dec 31, 2021 10-K 2023-02-28
Q3 2021 -$24.3M $71.7M +$94.3M Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 -$119M -$25.4M +$902K +3.42% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-07
Q1 2021 -$119M -$55.5M -$97.1M -234% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-07
Q4 2020 -$22.4M -$15M +$18.5M +55.3% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-28
Q3 2020 -$40.9M -$22.6M -$9.48M -72.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 -$31.5M -$26.3M +$28M +51.5% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-08
Q1 2020 -$59.5M $41.6M +$48M Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-08
Q4 2019 -$108M -$33.6M -$26.8M -397% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-16
Q3 2019 -$80.7M -$13.1M +$883K +6.3% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 -$81.6M -$54.3M -$45.4M -507% Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-09
Q1 2019 -$36.2M -$6.48M -$2.52M -63.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-09
Q4 2018 -$33.7M -$6.76M -$210K -3.21% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-16
Q3 2018 -$33.5M -$14M -$4.91M -53.9% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-16
Q2 2018 -$28.6M -$8.96M -$1.64M -22.4% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-16
Q1 2018 -$26.9M -$3.96M +$2.1M +34.6% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-16
Q4 2017 -$29M -$6.55M -$3.02M -85.4% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-01
Q3 2017 -$26M -$9.11M -$28.6M -147% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-01
Q2 2017 $2.58M -$7.32M -$825K -12.7% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-01
Q1 2017 $3.4M -$6.06M +$1.51M +20% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-01
Q4 2016 $1.89M -$3.53M +$6.8M +65.8% Oct 1, 2016 Dec 31, 2016 10-K 2018-04-02
Q3 2016 -$4.91M $19.5M +$29.2M Jul 1, 2016 Sep 30, 2016 10-K 2018-04-02
Q2 2016 -$34.1M -$6.49M +$415K +6.01% Apr 1, 2016 Jun 30, 2016 10-K 2018-04-02
Q1 2016 -$34.5M -$7.57M -$1.05M -16.1% Jan 1, 2016 Mar 31, 2016 10-K 2018-04-02
Q4 2015 -$33.5M -$10.3M -$2.19M -26.9% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-24
Q3 2015 -$31.3M -$9.69M +$981K +9.19% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-24
Q2 2015 -$32.2M -$6.91M +$1.22M +15% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-24
Q1 2015 -$33.5M -$6.52M +$698K +9.67% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-24
Q4 2014 -$34.2M -$8.14M -$3.07M -60.7% Oct 1, 2014 Dec 31, 2014 10-K 2016-03-25
Q3 2014 -$31.1M -$10.7M -$6.86M -180% Jul 1, 2014 Sep 30, 2014 10-K 2016-03-25
Q2 2014 -$24.2M -$8.12M -$4.49M -123% Apr 1, 2014 Jun 30, 2014 10-K 2016-03-25
Q1 2014 -$19.7M -$7.22M -$1.71M -31% Jan 1, 2014 Mar 31, 2014 10-K 2016-03-25
Q4 2013 -$18M -$5.07M Oct 1, 2013 Dec 31, 2013 10-K 2015-03-06
Q3 2013 -$3.81M Jul 1, 2013 Sep 30, 2013 10-K 2015-03-06
Q2 2013 -$3.63M Apr 1, 2013 Jun 30, 2013 10-K 2015-03-06
Q1 2013 -$5.51M Jan 1, 2013 Mar 31, 2013 10-K 2015-03-06
* An asterisk sign (*) next to the value indicates that the value is likely invalid.